Skin Cancer

Canadian Skin Patient Alliance lauds national Initial Recommendation for new melanoma drugs - Urges quick final approval

Published in Cancer Weekly, April 17th, 2012

2012 APR 17 -- Today the national drug-review agency, the pan-Canadian Oncology Drug Review (pCODR), announced it is recommending that provinces and territories should consider paying for the skin cancer drugs Yervoy (Ipilimumab) and Zelboraf (Vemurafenib) for the treatment of skin cancer patients whose melanoma has spread from the skin to other organs of the body.

"Today's 'Initial Recommendation' announcement from pCODR is good news for melanoma patients in Canada," said Christine Jackson, Executive Director of the Canadian Skin Patient Alliance (CSPA). "We are pleased that pCODR is moving quickly to evaluate these drugs and we hope that the remaining...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2012-04-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry